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Objective: To describe and compare demographic and clinical profile of patients newly initiated 
on aclidinium (ACL) or tiotropium (TIO) and identify factors associated with newly initiated 
ACL in real-life clinical practice during 2013 in Catalonia.
Design: We performed a population-based, retrospective, observational study with data obtained 
from the Information System for Research Development in Primary Care, a population database 
that contains information of 5.8 million inhabitants (more than 80% of the Catalan population). 
Patients over 40 years old, with a recorded diagnosis of COPD and newly initiated treatment 
with either ACL or TIO during the study period (January to December 2013), were selected. 
A descriptive analysis of demographic and clinical characteristics was performed, and treatment 
adherence was also assessed for both cohorts.
Results: A total of 8,863 individuals were identified, 4,293 initiated with ACL and 4,570 with 
TIO. They had a mean age of 69.4 years (standard deviation: 11.3), a median COPD duration 
of 3 years (interquartile range: 0–8), and 71% were males. Patients treated with ACL were 
older, with more respiratory comorbidities, a longer time since COPD diagnosis, worse forced 
expiratory volume in 1 second (% predicted), and with a higher rate of exacerbations during the 
previous year compared with TIO. It was found that 41.3% of patients with ACL and 62.3% 
of patients with TIO had no previous COPD treatment. Inhaled corticosteroid and long-acting 
β2-agonist were the most frequent concomitant medications (32.9% and 32.6%, respectively). 
Approximately 75% of patients were persistent with ACL or TIO at 3 months from the begin-
ning of treatment, and more than 50% of patients remained persistent at 9 months.
Conclusion: Patients initiated with ACL had more severe COPD and were taking more con-
comitant respiratory medications than patients initiated with TIO. ACL was more frequently 
initiated as part of triple therapy, while TIO was more frequently initiated as monotherapy.
Keywords: COPD, treatment, primary care, adherence
Introduction
Pharmacologic therapy for COPD aims to reduce and control symptoms, reduce the 
frequency and severity of exacerbations, and improve health status and exercise toler-
ance.1 Long-acting bronchodilators are the basis of COPD maintenance therapy,1,2 and 
among them, long-acting antimuscarinic agents (LAMAs) have demonstrated superior 
efficacy in prevention of exacerbations than long-acting β2-agonists (LABAs),3,4 and 
therefore, most guidelines recommend LAMAs as initial therapy for management of 
COPD.1,2
Tiotropium (TIO) was the first once-daily LAMA available, and lately aclidinium 
(ACL) is a twice-daily LAMA available for maintenance treatment to relieve symptoms 
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in COPD.5 ACL demonstrated similar efficacy and safety 
compared with TIO for the treatment of stable COPD,6,7 
with the twice-daily administration of ACL providing bet-
ter lung function in the second 12 hours of the day.6 Some 
studies have suggested that this second administration of the 
bronchodilator in the evening would result in better symptom 
control, even in patients with low levels of symptoms.7,8 It is 
not clear whether these differences are perceived by patients 
and prescribers in real life and may result in different pat-
terns of prescription.
The diagnosis and management of COPD in Spain 
is mostly made in primary care, and drug prescriptions 
for chronic diseases are only managed by primary care 
physicians. Therefore, the availability of large population-
based administrative databases from primary care records 
allows the evaluation of characteristics of patients receiving 
different therapies in an unbiased way. This is especially 
important when new treatments for specific conditions are 
available. With the administrative health care database of 
primary care in Catalonia (Spain), we have developed the 
current study with the objective to describe and compare 
the baseline characteristics of patients with COPD newly 
initiated either on TIO or ACL during 2013, 1 year after the 
launch of ACL in Spain, and identify factors associated with 
ACL prescription.
Methods
This was a population-based, retrospective, observational 
study aimed at describing baseline sociodemographic 
and clinical characteristics of COPD patients who started 
treatment with ACL or TIO during the study period (from 
January 1 to December 31, 2013). The index date was 
defined as the ACL or TIO initiation date and defined the 
start of the data collection period for each patient. Second-
ary evaluation included compliance to LAMAs during 1 
year after the index date. The data were obtained from the 
Information System for the Development of Research in 
Primary Care (SIDIAP) database, which contains anony-
mized computerized primary care medical records from 5.8 
million people in Catalonia, which represents more than 
80% of the total population.9 This database has been used 
and validated for epidemiological research in respiratory 
diseases including COPD.10
The inclusion criteria in the study were as follows: 1) 
initiation of treatment with either ACL or TIO during the 
study period; 2) a recorded diagnosis of COPD in the medi-
cal records; 3) age of 40 years; and 4) at least 3 months 
of follow-up after initiation of either treatment (extended 
COPD population).
A subpopulation analysis including a more restrictive 
definition of inclusion criteria was performed in order to 
validate the COPD diagnosis reported in the database (restric-
tive population). This analysis included patients who had a 
recorded diagnosis of COPD in the medical records as well as 
1) spirometry-confirmed airflow limitation (forced expiratory 
volume in 1 second [FEV
1
]/forced vital capacity ,0.7) at the 
time of diagnosis, or 2) were prescribed respiratory medica-
tion (Anatomical Therapeutic Chemical [ATC] code: R03) 
after diagnosis (restrictive COPD population).
The following variables were obtained at baseline: 
demographic and clinical characteristics, including age, sex, 
smoking history, and comorbidities. Diagnostic spirometry, 
exacerbations, and use of vaccines during the year before 
inclusion in the study and recorded in the database were 
also collected. Finally, concomitant treatment and type of 
prescription of the LAMA was assessed at the index date. 
Exacerbations were identified by diagnostic codes and by 
treatment when patients received antibiotics and/or oral 
corticosteroids in the absence of other codified infectious 
events such as tonsillitis or urinary infection.
Compliance was assessed in terms of persistence and 
in terms of adherence based on pharmacy records available 
until December 31, 2014, corresponding to a maximum of 
1 year after the index date. Theoretical medication use was 
calculated using information on dispensing date, total supply, 
and dosage regimen. Persistence was analyzed in terms of 
percentage of patients refilling prescriptions of LAMAs at 
3, 6, 9, and 12 months since index date. Adherence was 
analyzed in terms of medication possession ratio (MPR), 
defined as the number of doses dispensed in relation to the 
dispensing period. An MPR between 80% and 120% was 
used to define treatment-adherent patients.
This study was approved by the Ethics and Clinical 
Research Committee of the Jordi Gol Primary Care University 
Research Institute (Barcelona, Spain).
Statistical analysis
A descriptive analysis for both study populations (extended 
COPD population and restrictive population) was performed 
to describe baseline sociodemographic and clinical charac-
teristics of patients newly initiated on ACL or on TIO. For 
qualitative variables, absolute frequencies and corresponding 
percentages were calculated. Quantitative variable following 
a normal distribution were described by mean and standard 
deviation, while those that did not follow a normal distribu-
tion were describing using the median. We used independent 
t-tests for continuous data and χ2 tests for categorical data as 
appropriate for unadjusted comparisons between groups.
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Logistic regression model was performed to assess 
factors independently associated with newly initiated ACL 
versus TIO. Variables initially considered were: age, sex, 
time since COPD diagnosis, respiratory comorbidities, smok-
ing history, concomitant COPD treatment, visits to primary 
care physician, visits to pulmonologist, exacerbations, and 
spirometry.
All statistical tests were two-sided at the 5% significance 
level. Analyses were performed using Stata/SE version 14.2 
for Windows (Stata Corp. LP, College Station, TX, USA).
Results
A total of 105,727 subjects with recorded diagnosis of 
COPD were identified in the database during the reference 
year. Of them, 14,062 (13.3%) were identified as initiating 
treatment with either ACL or TIO in 2013. Of these patients, 
8,863 COPD patients fulfilled the inclusion criteria, 4,293 
initiated a treatment with ACL and 4,570 with TIO (Figure 1). 
Most patients had recommended dose prescribed of LAMA 
according to the summary of product characteristics (SmPC) 
(88.6% in patients with ACL and 88.9% with TIO).
In the extended COPD population, 71% were males, with 
a mean age of 69.4 years (standard deviation [SD]: 11.3), 
and a median duration of COPD of 3 years (interquartile 
range: 0–8). Most patients had smoking history (69.7%), 
and 40.3% were obese (body mass index 30). The most 
frequent respiratory comorbidities were asthma (14.4%), 
bronchiectasis (6.6%), and sleep apnea (5.2%). The most 
common nonrespiratory comorbidities were hypertension 
(57.3%), diabetes mellitus (24.4%), metabolic syndrome 
(21.3%), and anxiety or depression (15.1%).
A low percentage of spirometry in the previous year 
(21.0%), with a mean FEV
1
 (% predicted) of 62.1% (SD: 
20.3%) and a high percentage of patients with previous 
exacerbations (57.4%) were observed.
Patients treated with ACL were older, with more respi-
ratory comorbidities, a longer time since COPD diagnosis, 
worse FEV
1
 (% predicted), and a higher frequency of 
patients who suffered from an exacerbation the previous year 
compared with TIO (Table 1).
In the more restrictive population, there were more males, 
few never smokers, a higher frequency of spirometry in the 
previous year with worse FEV
1
 (%) values, and a higher 
rate of exacerbations in the previous year compared with 
the extended COPD population. The differences previously 
observed between the groups initiated with ACL or TIO 
persisted in this restrictive population (Table 1).
At the index date, 41.3% of patients newly initiated with 
ACL and 62.3% of patients newly initiated with TIO had 
no previous COPD treatment. The remaining patients were 
receiving concomitant COPD treatments. In general, use of 
concomitant treatments was higher in patients treated with 
ACL than in patients treated with TIO. Inhaled corticoster-
oids (ICS) and LABA were the most frequent concomitant 
medications (32.9% and 32.6%, respectively). All of these 
baseline characteristics were similar in the restrictive popu-
lation (Table 2).
Factors significantly associated with newly initiated ACL 
were male sex, a longer time since the COPD diagnosis, being 
a current smoker, receiving more concomitant COPD treat-
ments, having an exacerbation in the previous year, and a low 
percentage of spirometry in the previous year (Table 3).
We observed a high persistence to the treatment for both 
LAMAs. Approximately 75% of patients were persistent 
at 3 months from the beginning of LAMA treatment, and, 
although this percentage decreased gradually over time, at 
9 months more than 50% of patients remained persistent 
users (Figure 2).
The proportion of patient with an adequate MPR was also 
high, with a mean (SD) of MPR of 0.74 (0.35), and a median 
of 0.83. Using the definition of adherent patients taking into 
account an 80%# MPR 120%, 46.4% of patients treated 
with ACL and 54% of those treated with TIO were classified 
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Figure 1 selection of the samples of patients included in the study.





Table 1 Baseline characteristics of COPD patients newly initiated on aclidinium or tiotropium in 2013










sex (male), % 71.8 71.5 81.2 80.3
age (years), mean (sD) 70.3 (10.9) 68.5 (11.6)*** 69.8 (10.1) 67.3 (10.9)***
Tobacco consumption, % *** ***
nonsmoker 32.0 24.9 15.04 10.2
Current smoker 22.0 32.4 29.3 41.6
ex-smoker 43.4 39.9 53.5 44.8
Unknown 1.4 2.6 1.9 3.1
BMI (categorical), %
Underweight (BMI ,18.5) 1.4 1.7 1.4 1.9
normal weight (18.5# BMI ,25) 19.8 20.3 21.7 22.1
Overweight (25# BMI ,30) 38.6 37.6 39.4 38.8
Obese (BMI 30) 40.2 40.5 37.5 37.2
respiratory comorbidities, %
at least one respiratory comorbidity 31.4 26.6*** 24.3 17***
asthma 16.3 12.6*** 8 4.8***
Bronchiectasis 8.1 5.2*** 7.6 3.3***
sleep apnea 5.4 5.1 5.9 4.7
Other comorbidities, %
hypertension 59 55.7** 58.7 53***
Diabetes 25.5 23.4* 25 22.6*
Metabolic syndrome 22.4 20.3* 22 19.3*
anxiety or depression 15.6 14.6 14.4 12.2*
Time from COPD diagnosis (years), median 
(interquartile range)
5 (1–9) 1 (0–6)*** 3 (0–6) 0 (0–3)**
spirometry, n (%) in the previous year 812 (18.9) 1,113 (24.3)*** 518 (28.6) 651 (37.3)***
FeV1 (% predicted), mean (sD) 60.5 (20.4) 63.2 (20.0)** 57.6 (18.1) 60.5 (18.9)**
at least one exacerbation in the previous year, % 62.1 52.4*** 67.5 54.2***
Use of vaccines, %
Influenza 70.0 56.1*** 80.5 64.9***
Pneumococcus 80.2 67.6*** 69.7 53.2***
Notes: Data are expressed as n (%), unless otherwise indicated. Body mass index had missing values. *P,0.05, **P,0.01, ***P,0.001.
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; FeV1, forced expiratory volume in 1 second; sD, standard deviation.
Table 2 Baseline respiratory treatment of COPD patients newly initiated on aclidinium or tiotropium in 2013









Without current treatment, % 41.3 62.3a 43.4 68.6a
saBa 29.7 18.7a 28.8 15.6a
saMa 9.5 5.3a 10 4.1a
laBa 42.8 23a 41.9 18.8a
laMa 4.1 0a 4.9 0a
ICs 43.0 23.4a 40.0 17.4a
Treatment regimen, %*
laBa + ICsa 32.8 18.6a 29.3 13.6a
laBa + laMa + ICs 2.4 0a 1.4 0a
Notes: Data are expressed in %. aP,0.05. *laBa + ICs can also include saBa and saMa.
Abbreviations: COPD, chronic obstructive pulmonary disease; ICs, inhaled corticosteroid; laBa, long-acting β2 agonist; laMa, long-acting antimuscarinic agent; saBa, 
short-acting β2 agonist; saMa, short-acting antimuscarinic agent.




Characteristics of COPD patients initiating treatment with aCl or TIO
as treatment adherent (Table 3). The proportion of patients 
with an adequate adherence between the groups initiated 
with ACL or TIO in this restricted population was similar 
to extended COPD population (Table 4).
Discussion
Our study provides a description of the demographic and 
clinical profile of patients who initiated treatment with 
LAMAs in real-life clinical practice. The characteristics of 
patients corresponded to the usual profile of COPD patients 
who attended primary care in Southern European countries, 
almost two-thirds were male and mean age was 70 years.11–13 
When LAMA was initiated, approximately one-third of 
patients were already on a LABA/ICS combination, and 
therefore they were stepped up to triple therapy. Patients 
newly initiated on treatment with ACL had, in general, 
more severe COPD than patients newly initiated with TIO. 
Overall, adherence to treatment with LAMAs was high, 
especially in the first months of treatment, but decreased to 
~50% after 9 months.
Long-acting bronchodilators are the basis of COPD 
maintenance therapy, among them the LAMAs have dem-
onstrated similar bronchodilator efficacy as LABAs but with 
superior efficacy in prevention of exacerbations.3,4 Therefore, 
the recent GOLD strategy recommends LAMAs as initial 
therapy in virtually all categories of patients from A to D.1 
This recommendation is also included in most national 
guidelines of management of COPD,2 including the Spanish 
guidelines.14
The first LAMA developed for treatment of COPD was 
TIO, a once-daily LAMA that demonstrated a significant and 
persistent bronchodilator effect15 and a significant reduction 
Table 3 Independent factors associated with newly initiated aclidinium instead of tiotropium in 2013










age 0.99 0.99–1.00 0.74 1.00 0.99–1.01 0.14
sex (reference: male)
Female 0.88 0.79–0.97 0.02 0.98 0.82–1.17 0.85
Time from COPD diagnosis 1.04 1.03–1.05 ,0.001 1.09 1.07–1.11 ,0.001
Tobacco consumption 
(reference: nonsmoker)
Current smoker 0.73 0.64–0.84 ,0.001 0.66 0.52–0.84 0.001
ex-smoker 0.94 0.83–1.05 0.31 0.81 0.65–1.01 0.07
Unknown 0.53 0.38–0.74 ,0.001 0.65 0.40–1.05 0.08
Concomitant COPD 
treatment (reference: 0)
1.40 1.34–1.45 ,0.001 1.48 1.39–1.57 ,0.001
Visit to primary care 
physician (reference: 0)
1.01 1.00–1.01 0.001 1.02 1.01–1.03 ,0.001
exacerbations in the 
previous year (reference: 0)
1.10 1.05–1.15 ,0.001
spirometry (reference: no) 0.79 0.71–0.88 ,0.001 0.70 0.61–0.81 ,0.001
Note: Adjusted models only for significant variables.














Figure 2 Treatment persistence at 3, 6, and 9 months for aclidinium and tiotropium 
in the overall population.
Table 4 Compliance with laMa prescribed at study initiation













0.71 (36.2) 0.77 (33.9) 0.73 (34.9) 0.78 (32.9)
MPr, %
,80 49.0 41.8 48.9 42.9
80–120 46.4 54.0 46.7 53.4
.120 4.6 4.2 4.4 3.8
Note: Data are expressed in (%), unless otherwise indicated.
Abbreviations: laMa, long-acting antimuscarinic agent; MPr, medication poss-
ession ratio; sD, standard deviation.





in the risk of exacerbations.16 More recently, additional 
LAMAs have been introduced in the armamentarium for 
the long-term treatment of patients with COPD. Among 
them, ACL is a twice-daily LAMA, the efficacy and safety 
of which have been investigated in several studies demon-
strating a significant improvement in lung function, health 
status, and early morning, daytime, and nighttime symptoms 
in COPD patients.5–7 In comparative clinical trials, treatment 
with ACL was demonstrated to provide a higher area under 
the curve (AUC) for FEV
1
 during the second 12 hours of 
the day compared to TIO, as a result of the administration 
of the evening dose.6,7 This improvement in lung function 
resulted in a better control of symptoms compared with 
once-daily TIO.7 Although guidelines do not differentiate 
between different molecules in their recommendation for a 
LAMA, the different profiles of ACL and TIO may influence 
the perception of prescribers; therefore, we investigated the 
demographic and clinical profile of patients newly initiated 
with these two LAMAs over a period of 1 year. TIO was 
launched in Spain in 2002 and ACL was launched in 2013, 
thus during the period of the study they were the only two 
LAMAs available.
Our results showed that patients who initiated treatment 
with ACL had a more severe disease compared with patients 
with TIO. This increased severity was demonstrated by an 
older age, longer duration of COPD, higher frequency of 
comorbidities, worse lung function, and more frequent exac-
erbations in the previous year, among other variables. Fur-
thermore, patients initiated with ACL were more frequently 
stepped up from previous treatments compared with patients 
initiated with TIO. Approximately 40% of patients initiating 
ACL were already on LABA/ICS compared with 23% of 
patients initiated with TIO. This means that the most frequent 
indication for ACL was the initiation of triple therapy; but in 
contrast, up to 62% of patients initiated TIO as monotherapy. 
This suggests that primary care physicians selected ACL 
for the more severe patients who were uncontrolled with 
their usual medication, but prescribed more often TIO in 
treatment-naïve patients as monotherapy. This observation 
may be related to the more recent launch of ACL, because 
newly available drugs tend to be used in more severe patients 
and those not responding to existing therapies. Moreover, 
it can be related to the effect of ACL on improvement and 
control of symptoms.8 Another factor would be that the 
LABA/ICS combinations available during the period of the 
study were twice daily, and therefore adding a twice-daily 
LAMA would be a reasonable option for patients in need of 
triple therapy.
The introduction of new drugs in more severe patients 
is illustrated by a French study analyzing the impact of the 
introduction of TIO in 2006. Similar to our results, the authors 
found that in 32.5% of cases, the new LAMA was added to 
LABA/ICS as triple therapy and very infrequently used as 
monotherapy.17 Also in the UK, the most frequent pathway 
to triple therapy was the addition of a LAMA to the existing 
treatment with a LABA/ICS.18 In the same study, the authors 
observed that 25% of patients initiating therapy for COPD 
were on triple therapy within 1 year, and the main driver for 
initiating this therapy was the history of exacerbations.18
Interestingly, only 20% of the study population had a 
spirometry performed in the previous year, and due to the 
characteristics of the study it is not possible to know where 
these spirometries were performed. This low use of spirom-
etry in primary care has been recognized in Spain10,12,13,19 
and in other countries.20–22 This indicates that primary care 
physicians rely on other factors in order to make decisions 
about treatment. De Miguel et al12 in a large cohort of patients 
in primary care identified increasing dyspnea and impair-
ment in quality of life as the main drivers for increasing 
therapy in COPD. In addition, Brusselle et al18 observed that 
history of exacerbations was the main factor associated with 
the prescription of triple therapy. All these studies suggest 
that lung function is not the main factor driving changes in 
COPD treatment in primary care. In agreement with this 
reality, the GOLD strategy recommends different treatment 
options based on history of exacerbations and intensity of 
symptoms,1 and a new algorithm of pharmacologic treatment 
has been proposed based on the degree of dyspnea and the 
frequency and phenotype or exacerbations.23
The administration of bronchodilator treatment twice 
daily has been associated with a better control of symptoms 
over the whole day.7,8,24 A recent observational study in Spain 
showed that 52% of patients experienced respiratory symp-
toms throughout the day in spite of 62% being treated with 
triple therapy, and more symptomatic patients had poorer 
quality of life and more frequent anxiety and depression.25 
The high prevalence of symptoms may partly explain the 
increase in the prescription of twice-daily ACL in more 
severe patients compared with TIO.
Adherence to treatment and the correct use of the inhaler 
device are essential for therapeutic success. In general, adher-
ence to inhaled medication in COPD is poor.20 In our study, 
persistence with LAMAs was initially high and decreased 
progressively to ~50% after 1 year follow-up. This is very 
similar to the 53% of persistence with TIO at 1 year observed 
in a Canadian study.21 A recent Italian study observed a 
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very high rate of discontinuation of bronchodilators and an 
increased risk of hospitalization and death associated with 
discontinuation;26 therefore, strategies to increase adherence 
are necessary to improve outcomes of therapy.20,27 Interest-
ingly, persistence with therapy was very similar for ACL and 
TIO despite the different posology. This was also observed by 
Izquierdo et al28 in another population-based study in Spain 
in which they observed a high rate of compliance with treat-
ment with LAMAs and no differences between the different 
products. In any case, patients initiating treatment with ACL 
or TIO in our study differed in variables that have been shown 
to have an impact on treatment adherence, for example, 
severity of the disease, age, and number of concomitant 
medications.20,21,29 Consequently, these important differ-
ences did not allow us to formally compare the rates of 
persistence between both drugs. Similarly, the medication 
possession ratios (MPR) in our population were high and 
ranged from 73% to 79%, very similar to the 78% observed 
in the Netherlands for LAMAs.30
Our study has some limitations. Studies based on large 
clinical databases are subjected to possible diagnostic and 
miscoding bias and invalid data.31 In order to ensure the 
diagnosis of COPD, we used more restrictive selection 
criteria that included a spirometric diagnosis of COPD 
and prescription of respiratory medication after diagnosis. 
Interestingly, the results in this more restrictive popula-
tion were almost identical to those obtained in the global 
population.
Persistence of therapy with ACL and TIO was very 
similar; however, due to the different characteristics of 
the patients initiated with ACL or TIO it was not possible 
to compare adherence to treatment in an unbiased way. 
In addition, we could not investigate the type of device 
used (Handihaler or Respimat) or the inhalation technique, 
which could have provided additional information. Studies 
specifically designed to analyze compliance should be 
conducted.
Conclusion
In conclusion, our study shows that patients initiated with 
ACL in primary care had more severe disease and used more 
respiratory medications than patients initiated with TIO. 
Adherence and persistence to treatment with LAMAs was 
high in real-life clinical practice.
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